[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
January 26, 2005

Experts Point to Lessons Learned From Controversy Over Rofecoxib Safety

JAMA. 2005;293(4):413-414. doi:10.1001/jama.293.4.413

Chicago—Now that rofecoxib has been pulled from the market due to life-threatening adverse cardiovascular events, which had reportedly been evident 4 years ago, patients and physicians are left with many questions regarding the safety of other drugs that preferentially inhibit the cyclooxygenase-2 (COX-2) enzyme and the shortcomings in the government’s drug monitoring system in general.

First Page Preview View Large
First page PDF preview
First page PDF preview